Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

00:44 EST 28th November 2014 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 27,000+

Wednesday 26th November 2014

ACO Coalition Looks at Managed Care Tools to Help Employers, Promote Patient Engagement

The ACO and Emerging Healthcare Delivery Coalition, an initiative of The American Journal of Managed Care, held its most recent WebEx session this week. Participants discussed strategies and technologies that both employers and healthcare organizations can use to get patients to take ownership over their own care. PLAINSBORO, N.J. (PRWEB) November 26, 2014 Patient engagement is a new term for a s...

UPDATE 1-Medtronic gets U.S. antitrust OK to buy Covidien with divestiture

WASHINGTON, Nov 26 (Reuters) - Medtronic Inc has won U.S. antitrust approval to buy Dublin-based Covidien Plc on condition that it sell its drug-coated balloon catheter business, the Federal Trade Commission said on Wednesday.

Turkey Company News: A Court Case, An Acquisition And Moves By AZ

Recent developments in Turkey’s rapidly changing drug market include an embezzlement case involving former executives of the country’s largest pharma firm, an acquisition and personnel changes at AstraZeneca’s local subsidiary.

Medtronic gets US antitrust approval to buy Covidien with divestiture

WASHINGTON, Nov 26 (Reuters) - Medtronic Inc has won U.S. antitrust approval to buy Covidien PLC on condition that it sell its drug-coated balloon catheter business, the Federal Trade Commission said on Wednesday.

Nature Publication Co-Authored by Robert H. Pierce, Chief Scientific Officer, OncoSec Medical

Data Support Expanding the Application of Checkpoint Inhibitors with OncoSec’s ImmunoPulse Therapy Research conducted by Robert H. Pierce, MD, Chief Scientific Officer at OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, was published in the November 27, 2014 issue of the journal Nature. Th...

Fitch Affirms Martin County Hospital District, TX LT Bonds at 'BBB'; Outlook Stable

Fitch Ratings has affirmed the following Martin County Hospital District, Texas (MCHD) ratings: --$21 million combination limited tax and revenue bonds, series 2011A and 2011B (taxable) at 'BBB'. The Rating Outlook is Stable. SECURITY Direct obligations of the district secured payable from a limited ad valo...

Teens with a history of TBI are nearly four times more likely to have used crystal meth

Ontario students between Grades 9 and 12 who said they had a traumatic brain injury in their lifetime, also reported drug use rates two to four times higher than peers with no history of TBI, according to research published today in The Journal of He...

ImaCor Announces All-In-One Hemodynamic Management Platform

Cutting Edge Technology Provides The Whole Picture In Critical Care ImaCor, Inc., the developer of the world’s first and only hemodynamic transesophageal echocardiography (

Xarelto Lawsuit Plaintiffs File Briefs In Support of Federal Consolidation, Bernstein Liebhard LLP Reports

The Firm is representing plaintiffs in Xarelto lawsuits who allegedly experienced uncontrollable bleeding, stroke, deep vein thrombosis, and other serious complications related to its use. New York, New York (PRWEB) November 26, 2014 As Xarelto lawsuits (http://www.xareltolawsuit2015.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that plaintiffs involved in these cases have ...

Genomics Ltd. raises L10.3 million

Sequencing analytics play and University of Oxford spin-out Genomics Ltd. (Oxford, U.K.) raised L10.3 million ($16.1 million) in its "first significant" round of funding, according to CEO John Colenutt. New investors Invesco Perpetual; Lansdowne Part...

CRL for daclatasvir sets back BMS's HCV program

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA issued a complete response letter for daclatasvir on Wednesday, requesting additional safety and efficacy data for the HCV drug in combination with other antiviral agents. BMS said its NDA for the selectiv...

Astellas: Data show fidaxomicin's efficacy, cost savings

Astellas Pharma Inc. (Tokyo:4503) said a pooled analysis showed that patients receiving fidaxomicin to treat Clostridium difficile infection (CDI) had reduced mortality, recurrence rates and healthcare costs compared with standard-of-care (SOC) vanco...

uniQure partner prices gene therapy Glybera at EUR 1.1M

Chiesi Farmaceutici S.p.A (Parma, Italy) has filed a pricing dossier for Glybera alipogene tiparvovec with Germany's Federal Joint Committee (G-BA) that pegs the price of the gene therapy at over EUR 1 million. Chiesi has commercial rights to Glybera...

Exclusive: First gene therapy drug sets million-euro price record

FRANKFURT/LONDON (Reuters) - The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag, a new record for a medicine to treat a rare disease.

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

Human cancers, including breast cancers, comprise clones differing in mutation content. Clones evolve dynamically in space and time following principles of Darwinian evolution, underpinning important emergent features such as drug resistance and meta...

Bristol-Myers: FDA blocks hepatitis C drug daclatasvir as part of combo, requires more data

U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir.

With age, we lose our visual learning filter

Older people can actually take in and learn from visual information more readily than younger people do, according to new evidence reported in the Cell Press journal Current Biology on November 26. This surprising discovery is explained by an apparen...

Steer clear of cold meds for babies, FDA advises

(HealthDay)—Most babies and young children don't need medicines if they have a cold, the U.S. Food and Drug Administration says.

Two studies identify a detectable, pre-cancerous state in the blood

BOSTON, Nov. 26, 2014 /PRNewswire/ -- Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, ...

Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA

ALISO VIEJO, Calif., Nov. 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for AVP-825. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel ...

Creating Low Toxin Potato

A group of researchers from RIKEN Center for Sustainable Resource Science led by Kazuki Saito has discovered a way in producing safer potatoes. This discovery is necessary since potatoes secrete solanine and chacocine, toxins also known as steroidal glycoalkoids (SGA), which provide defense for growing sprouts against potential pest. Presence of th...

FDA declines to approve Bristol-Myers hepatitis drug

Nov 26 (Reuters) - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.

Global Bioenergies Announces Break-Through in Direct Biological Production of Butadiene

Regulatory News: Global Bioenergies (Paris:ALGBE) (Alternext Paris: ALGBE) announces having succeeded in the production of bio-sourced butadiene by direct fermentation. It is the first time ever an entirely biological production process -i.e. without any chemical step- is reported for butadiene, one of the most important petrochemical building blo...

NEMUS Bioscience Is Now Quoted on the OTC Bulletin Board Under the Ticker Symbol of “NMUS”

Biopharmaceutical Company Developing Cannabis-Based Medicines with the University of Mississippi NEMUS Bioscience, Inc. a Nevada corporation (the “Company”), announced that its common stock is now eligible for quotation on the OTC Bulletin Board under the ticker symbol (NMUS). NEMUS completed a reverse merger with Load Guard Logistics, Inc. (“LGL...

Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C (HCV). The initial daclatasvir NDA s


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks